Christopher Morrison
If the majority of the world’s largest drugmakers are embracing both specialty products and externalization strategies to address the industry’s...
The recent diabetes alliance between Bristol-Myers Squibb and AstraZeneca on two late-stage clinical compounds highlights some of the different ways pharmaceutical companies are embracing both specialty products and externalization strategies to address the industry's growing pipeline problem. BMS and AZ are pursuing different approaches but in diabetes, those strategies are complementary: AZ's unabashed externalization and muscular primary care marketing suits BMS's gradual weaning off the blockbuster model.
Christopher Morrison
If the majority of the world’s largest drugmakers are embracing both specialty products and externalization strategies to address the industry’s...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.